Novan, Inc.

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, VRTX has a market cap of 121.3B. Regarding current trading prices, NOVN is priced at $0.09, while VRTX trades at $477.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas VRTX's P/E ratio is 31.98. In terms of profitability, NOVN's ROE is -1.71%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, NOVN is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check VRTX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, REGN has a market cap of 81.8B. Regarding current trading prices, NOVN is priced at $0.09, while REGN trades at $787.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas REGN's P/E ratio is 18.99. In terms of profitability, NOVN's ROE is -1.71%, compared to REGN's ROE of +0.15%. Regarding short-term risk, NOVN is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check REGN's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, NOVN is priced at $0.09, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas VRNA's P/E ratio is -102.80. In terms of profitability, NOVN's ROE is -1.71%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, NOVN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check VRNA's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ARGX has a market cap of 46.4B. Regarding current trading prices, NOVN is priced at $0.09, while ARGX trades at $749.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ARGX's P/E ratio is 32.06. In terms of profitability, NOVN's ROE is -1.71%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, NOVN is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ARGX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ALNY has a market cap of 43.4B. Regarding current trading prices, NOVN is priced at $0.09, while ALNY trades at $327.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ALNY's P/E ratio is 142.77. In terms of profitability, NOVN's ROE is -1.71%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, NOVN is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ALNY's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NOVN is priced at $0.09, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NOVN's ROE is -1.71%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NOVN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check SGEN's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, INSM has a market cap of 32.3B. Regarding current trading prices, NOVN is priced at $0.09, while INSM trades at $149.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas INSM's P/E ratio is -23.35. In terms of profitability, NOVN's ROE is -1.71%, compared to INSM's ROE of -1.68%. Regarding short-term risk, NOVN is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check INSM's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, BNTX has a market cap of 25B. Regarding current trading prices, NOVN is priced at $0.09, while BNTX trades at $103.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas BNTX's P/E ratio is -36.94. In terms of profitability, NOVN's ROE is -1.71%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, NOVN is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check BNTX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, MRNA has a market cap of 22.8B. Regarding current trading prices, NOVN is priced at $0.09, while MRNA trades at $57.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas MRNA's P/E ratio is -7.96. In terms of profitability, NOVN's ROE is -1.71%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, NOVN is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check MRNA's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, UTHR has a market cap of 21.5B. Regarding current trading prices, NOVN is priced at $0.09, while UTHR trades at $490.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas UTHR's P/E ratio is 17.59. In terms of profitability, NOVN's ROE is -1.71%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, NOVN is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check UTHR's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ROIV has a market cap of 21.1B. Regarding current trading prices, NOVN is priced at $0.09, while ROIV trades at $29.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ROIV's P/E ratio is -25.23. In terms of profitability, NOVN's ROE is -1.71%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, NOVN is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ROIV's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, RPRX has a market cap of 20.3B. Regarding current trading prices, NOVN is priced at $0.09, while RPRX trades at $47.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas RPRX's P/E ratio is 26.65. In terms of profitability, NOVN's ROE is -1.71%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, NOVN is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check RPRX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NOVN is priced at $0.09, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NOVN's ROE is -1.71%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, NOVN is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check BGNE's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, INCY has a market cap of 19.7B. Regarding current trading prices, NOVN is priced at $0.09, while INCY trades at $98.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas INCY's P/E ratio is 15.72. In terms of profitability, NOVN's ROE is -1.71%, compared to INCY's ROE of +0.29%. Regarding short-term risk, NOVN is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check INCY's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, RVMD has a market cap of 19.6B. Regarding current trading prices, NOVN is priced at $0.09, while RVMD trades at $101.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas RVMD's P/E ratio is -19.50. In terms of profitability, NOVN's ROE is -1.71%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, NOVN is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check RVMD's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NOVN is priced at $0.09, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NOVN's ROE is -1.71%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, NOVN is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check DNA-WT's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, GMAB has a market cap of 17.4B. Regarding current trading prices, NOVN is priced at $0.09, while GMAB trades at $28.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas GMAB's P/E ratio is 18.30. In terms of profitability, NOVN's ROE is -1.71%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, NOVN is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check GMAB's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, NOVN is priced at $0.09, while ASND trades at $241.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ASND's P/E ratio is -54.53. In terms of profitability, NOVN's ROE is -1.71%, compared to ASND's ROE of +1.28%. Regarding short-term risk, NOVN is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ASND's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, BBIO has a market cap of 12.9B. Regarding current trading prices, NOVN is priced at $0.09, while BBIO trades at $66.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas BBIO's P/E ratio is -17.60. In terms of profitability, NOVN's ROE is -1.71%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, NOVN is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check BBIO's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, IONS has a market cap of 12.9B. Regarding current trading prices, NOVN is priced at $0.09, while IONS trades at $79.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas IONS's P/E ratio is -33.38. In terms of profitability, NOVN's ROE is -1.71%, compared to IONS's ROE of -0.69%. Regarding short-term risk, NOVN is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check IONS's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NOVN is priced at $0.09, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NOVN's ROE is -1.71%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NOVN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check KRTX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, NOVN is priced at $0.09, while BMRN trades at $60.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas BMRN's P/E ratio is 33.57. In terms of profitability, NOVN's ROE is -1.71%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, NOVN is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check BMRN's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, JAZZ has a market cap of 11.6B. Regarding current trading prices, NOVN is priced at $0.09, while JAZZ trades at $188.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas JAZZ's P/E ratio is -32.25. In terms of profitability, NOVN's ROE is -1.71%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, NOVN is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check JAZZ's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, SMMT has a market cap of 11.4B. Regarding current trading prices, NOVN is priced at $0.09, while SMMT trades at $15.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas SMMT's P/E ratio is -10.68. In terms of profitability, NOVN's ROE is -1.71%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, NOVN is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check SMMT's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, EXEL has a market cap of 11.2B. Regarding current trading prices, NOVN is priced at $0.09, while EXEL trades at $41.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas EXEL's P/E ratio is 15.00. In terms of profitability, NOVN's ROE is -1.71%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, NOVN is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check EXEL's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, NOVN is priced at $0.09, while MDGL trades at $434.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas MDGL's P/E ratio is -33.84. In terms of profitability, NOVN's ROE is -1.71%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, NOVN is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check MDGL's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NOVN is priced at $0.09, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NOVN's ROE is -1.71%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NOVN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check RXDX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, IBRX has a market cap of 9.2B. Regarding current trading prices, NOVN is priced at $0.09, while IBRX trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas IBRX's P/E ratio is -23.63. In terms of profitability, NOVN's ROE is -1.71%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, NOVN is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check IBRX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ARWR has a market cap of 9.1B. Regarding current trading prices, NOVN is priced at $0.09, while ARWR trades at $65.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ARWR's P/E ratio is 40.69. In terms of profitability, NOVN's ROE is -1.71%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, NOVN is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ARWR's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, TECH has a market cap of 9.1B. Regarding current trading prices, NOVN is priced at $0.09, while TECH trades at $57.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas TECH's P/E ratio is 109.15. In terms of profitability, NOVN's ROE is -1.71%, compared to TECH's ROE of +0.04%. Regarding short-term risk, NOVN is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check TECH's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NOVN is priced at $0.09, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NOVN's ROE is -1.71%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, NOVN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check IMGN's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, NOVN is priced at $0.09, while PCVX trades at $60.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas PCVX's P/E ratio is -12.38. In terms of profitability, NOVN's ROE is -1.71%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, NOVN is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check PCVX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, AXSM has a market cap of 8.4B. Regarding current trading prices, NOVN is priced at $0.09, while AXSM trades at $164.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas AXSM's P/E ratio is -44.49. In terms of profitability, NOVN's ROE is -1.71%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, NOVN is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check AXSM's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NOVN is priced at $0.09, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NOVN's ROE is -1.71%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, NOVN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check BPMC's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, HALO has a market cap of 8.3B. Regarding current trading prices, NOVN is priced at $0.09, while HALO trades at $70.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas HALO's P/E ratio is 27.35. In terms of profitability, NOVN's ROE is -1.71%, compared to HALO's ROE of +0.93%. Regarding short-term risk, NOVN is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check HALO's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NOVN is priced at $0.09, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CERE's P/E ratio is -16.47. In terms of profitability, NOVN's ROE is -1.71%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NOVN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CERE's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, KRYS has a market cap of 7.7B. Regarding current trading prices, NOVN is priced at $0.09, while KRYS trades at $265.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas KRYS's P/E ratio is 38.80. In terms of profitability, NOVN's ROE is -1.71%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, NOVN is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check KRYS's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, NOVN is priced at $0.09, while ABVX trades at $116.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ABVX's P/E ratio is -22.37. In terms of profitability, NOVN's ROE is -1.71%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, NOVN is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ABVX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CYTK has a market cap of 7.6B. Regarding current trading prices, NOVN is priced at $0.09, while CYTK trades at $62.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CYTK's P/E ratio is -9.88. In terms of profitability, NOVN's ROE is -1.71%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, NOVN is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CYTK's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, NOVN is priced at $0.09, while NUVL trades at $102.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas NUVL's P/E ratio is -19.26. In terms of profitability, NOVN's ROE is -1.71%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, NOVN is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check NUVL's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, NOVN is priced at $0.09, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas MTSR's P/E ratio is -23.58. In terms of profitability, NOVN's ROE is -1.71%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, NOVN is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check MTSR's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, NOVN is priced at $0.09, while KYMR trades at $86.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas KYMR's P/E ratio is -23.92. In terms of profitability, NOVN's ROE is -1.71%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, NOVN is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check KYMR's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, PRAX has a market cap of 6.9B. Regarding current trading prices, NOVN is priced at $0.09, while PRAX trades at $325.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas PRAX's P/E ratio is -24.14. In terms of profitability, NOVN's ROE is -1.71%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, NOVN is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check PRAX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, NOVN is priced at $0.09, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas MRUS's P/E ratio is -17.05. In terms of profitability, NOVN's ROE is -1.71%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, NOVN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check MRUS's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, NOVN is priced at $0.09, while BLTE trades at $177.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas BLTE's P/E ratio is -92.60. In terms of profitability, NOVN's ROE is -1.71%, compared to BLTE's ROE of -0.34%. Regarding short-term risk, NOVN is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check BLTE's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ACLX has a market cap of 6.6B. Regarding current trading prices, NOVN is priced at $0.09, while ACLX trades at $114.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ACLX's P/E ratio is -29.08. In terms of profitability, NOVN's ROE is -1.71%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, NOVN is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ACLX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NOVN is priced at $0.09, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas RETA's P/E ratio is -66.29. In terms of profitability, NOVN's ROE is -1.71%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NOVN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check RETA's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, NOVN is priced at $0.09, while RYTM trades at $91.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas RYTM's P/E ratio is -29.35. In terms of profitability, NOVN's ROE is -1.71%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, NOVN is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check RYTM's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, PTGX has a market cap of 6.1B. Regarding current trading prices, NOVN is priced at $0.09, while PTGX trades at $94.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas PTGX's P/E ratio is -46.26. In terms of profitability, NOVN's ROE is -1.71%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, NOVN is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check PTGX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, COGT has a market cap of 6B. Regarding current trading prices, NOVN is priced at $0.09, while COGT trades at $37.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas COGT's P/E ratio is -17.14. In terms of profitability, NOVN's ROE is -1.71%, compared to COGT's ROE of -1.00%. Regarding short-term risk, NOVN is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check COGT's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CRSP has a market cap of 5.8B. Regarding current trading prices, NOVN is priced at $0.09, while CRSP trades at $60.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CRSP's P/E ratio is -9.71. In terms of profitability, NOVN's ROE is -1.71%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, NOVN is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CRSP's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, NOVN is priced at $0.09, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CDTX's P/E ratio is -19.77. In terms of profitability, NOVN's ROE is -1.71%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, NOVN is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CDTX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CAI has a market cap of 5.6B. Regarding current trading prices, NOVN is priced at $0.09, while CAI trades at $19.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CAI's P/E ratio is -5.64. In terms of profitability, NOVN's ROE is -1.71%, compared to CAI's ROE of +1.97%. Regarding short-term risk, NOVN is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CAI's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NOVN is priced at $0.09, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NOVN's ROE is -1.71%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NOVN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ABCM's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NOVN is priced at $0.09, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NOVN's ROE is -1.71%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NOVN is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ISEE's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, IMVT has a market cap of 5.5B. Regarding current trading prices, NOVN is priced at $0.09, while IMVT trades at $27.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas IMVT's P/E ratio is -10.14. In terms of profitability, NOVN's ROE is -1.71%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, NOVN is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check IMVT's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, NOVN is priced at $0.09, while PTCT trades at $64.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas PTCT's P/E ratio is 7.49. In terms of profitability, NOVN's ROE is -1.71%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, NOVN is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check PTCT's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, NOVN is priced at $0.09, while FBIOX trades at $25.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas FBIOX's P/E ratio is N/A. In terms of profitability, NOVN's ROE is -1.71%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, NOVN is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check FBIOX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CELC has a market cap of 5.2B. Regarding current trading prices, NOVN is priced at $0.09, while CELC trades at $112.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CELC's P/E ratio is -30.48. In terms of profitability, NOVN's ROE is -1.71%, compared to CELC's ROE of -1.79%. Regarding short-term risk, NOVN is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CELC's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CGON has a market cap of 5B. Regarding current trading prices, NOVN is priced at $0.09, while CGON trades at $61.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CGON's P/E ratio is -30.03. In terms of profitability, NOVN's ROE is -1.71%, compared to CGON's ROE of -0.23%. Regarding short-term risk, NOVN is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CGON's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ALKS has a market cap of 4.9B. Regarding current trading prices, NOVN is priced at $0.09, while ALKS trades at $29.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ALKS's P/E ratio is 20.45. In terms of profitability, NOVN's ROE is -1.71%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, NOVN is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ALKS's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, SRRK has a market cap of 4.8B. Regarding current trading prices, NOVN is priced at $0.09, while SRRK trades at $47.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas SRRK's P/E ratio is -15.06. In terms of profitability, NOVN's ROE is -1.71%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, NOVN is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check SRRK's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ERAS has a market cap of 4.7B. Regarding current trading prices, NOVN is priced at $0.09, while ERAS trades at $15.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ERAS's P/E ratio is -35.16. In terms of profitability, NOVN's ROE is -1.71%, compared to ERAS's ROE of -0.33%. Regarding short-term risk, NOVN is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ERAS's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, NOVN is priced at $0.09, while MIRM trades at $93.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas MIRM's P/E ratio is -110.76. In terms of profitability, NOVN's ROE is -1.71%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, NOVN is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check MIRM's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, TGTX has a market cap of 4.6B. Regarding current trading prices, NOVN is priced at $0.09, while TGTX trades at $29.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas TGTX's P/E ratio is 10.54. In terms of profitability, NOVN's ROE is -1.71%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, NOVN is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check TGTX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, NOVN is priced at $0.09, while FOLD trades at $14.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas FOLD's P/E ratio is -159.22. In terms of profitability, NOVN's ROE is -1.71%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, NOVN is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check FOLD's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, NOVN is priced at $0.09, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas AKRO's P/E ratio is -14.57. In terms of profitability, NOVN's ROE is -1.71%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, NOVN is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check AKRO's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NOVN is priced at $0.09, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NOVN's ROE is -1.71%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NOVN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ALPN's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NOVN is priced at $0.09, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas OPT's P/E ratio is -1.52. In terms of profitability, NOVN's ROE is -1.71%, compared to OPT's ROE of +0.88%. Regarding short-term risk, NOVN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check OPT's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NOVN is priced at $0.09, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NOVN's ROE is -1.71%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NOVN is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check MRTX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, LGND has a market cap of 4.1B. Regarding current trading prices, NOVN is priced at $0.09, while LGND trades at $208.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas LGND's P/E ratio is 92.05. In terms of profitability, NOVN's ROE is -1.71%, compared to LGND's ROE of +0.14%. Regarding short-term risk, NOVN is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check LGND's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CRNX has a market cap of 4.1B. Regarding current trading prices, NOVN is priced at $0.09, while CRNX trades at $39.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CRNX's P/E ratio is -8.72. In terms of profitability, NOVN's ROE is -1.71%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, NOVN is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CRNX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, APGE has a market cap of 4B. Regarding current trading prices, NOVN is priced at $0.09, while APGE trades at $72.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas APGE's P/E ratio is -16.51. In terms of profitability, NOVN's ROE is -1.71%, compared to APGE's ROE of +0.00%. Regarding short-term risk, NOVN is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check APGE's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ACAD has a market cap of 4B. Regarding current trading prices, NOVN is priced at $0.09, while ACAD trades at $23.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ACAD's P/E ratio is 15.07. In terms of profitability, NOVN's ROE is -1.71%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, NOVN is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ACAD's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ADMA has a market cap of 3.9B. Regarding current trading prices, NOVN is priced at $0.09, while ADMA trades at $16.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ADMA's P/E ratio is 19.23. In terms of profitability, NOVN's ROE is -1.71%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, NOVN is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ADMA's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, TERN has a market cap of 3.8B. Regarding current trading prices, NOVN is priced at $0.09, while TERN trades at $42.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas TERN's P/E ratio is -41.70. In terms of profitability, NOVN's ROE is -1.71%, compared to TERN's ROE of -0.30%. Regarding short-term risk, NOVN is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check TERN's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CORT has a market cap of 3.8B. Regarding current trading prices, NOVN is priced at $0.09, while CORT trades at $35.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CORT's P/E ratio is 44.61. In terms of profitability, NOVN's ROE is -1.71%, compared to CORT's ROE of +0.15%. Regarding short-term risk, NOVN is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CORT's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NOVN is priced at $0.09, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NOVN's ROE is -1.71%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NOVN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check RYZB's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NOVN is priced at $0.09, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NOVN's ROE is -1.71%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, NOVN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CBAY's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, NOVN is priced at $0.09, while VKTX trades at $32.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas VKTX's P/E ratio is -10.08. In terms of profitability, NOVN's ROE is -1.71%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, NOVN is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check VKTX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, GPCR has a market cap of 3.6B. Regarding current trading prices, NOVN is priced at $0.09, while GPCR trades at $63.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas GPCR's P/E ratio is -17.25. In terms of profitability, NOVN's ROE is -1.71%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, NOVN is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check GPCR's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CNTA has a market cap of 3.6B. Regarding current trading prices, NOVN is priced at $0.09, while CNTA trades at $26.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CNTA's P/E ratio is -14.13. In terms of profitability, NOVN's ROE is -1.71%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, NOVN is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CNTA's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, NAMS has a market cap of 3.6B. Regarding current trading prices, NOVN is priced at $0.09, while NAMS trades at $31.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas NAMS's P/E ratio is -18.13. In terms of profitability, NOVN's ROE is -1.71%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, NOVN is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check NAMS's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, NOVN is priced at $0.09, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas SWTX's P/E ratio is -13.78. In terms of profitability, NOVN's ROE is -1.71%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, NOVN is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check SWTX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, KNSA has a market cap of 3.5B. Regarding current trading prices, NOVN is priced at $0.09, while KNSA trades at $47.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas KNSA's P/E ratio is 105.04. In terms of profitability, NOVN's ROE is -1.71%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, NOVN is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check KNSA's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, XENE has a market cap of 3.3B. Regarding current trading prices, NOVN is priced at $0.09, while XENE trades at $43.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas XENE's P/E ratio is -11.07. In terms of profitability, NOVN's ROE is -1.71%, compared to XENE's ROE of -0.56%. Regarding short-term risk, NOVN is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check XENE's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, TARS has a market cap of 3.2B. Regarding current trading prices, NOVN is priced at $0.09, while TARS trades at $76.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas TARS's P/E ratio is -47.92. In terms of profitability, NOVN's ROE is -1.71%, compared to TARS's ROE of -0.20%. Regarding short-term risk, NOVN is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check TARS's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, DNLI has a market cap of 3.2B. Regarding current trading prices, NOVN is priced at $0.09, while DNLI trades at $20.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas DNLI's P/E ratio is -6.98. In terms of profitability, NOVN's ROE is -1.71%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, NOVN is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check DNLI's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, EWTX has a market cap of 3.1B. Regarding current trading prices, NOVN is priced at $0.09, while EWTX trades at $28.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas EWTX's P/E ratio is -18.39. In terms of profitability, NOVN's ROE is -1.71%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, NOVN is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check EWTX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, IDYA has a market cap of 3B. Regarding current trading prices, NOVN is priced at $0.09, while IDYA trades at $34.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas IDYA's P/E ratio is -27.09. In terms of profitability, NOVN's ROE is -1.71%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, NOVN is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check IDYA's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, CPRX has a market cap of 3B. Regarding current trading prices, NOVN is priced at $0.09, while CPRX trades at $24.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas CPRX's P/E ratio is 14.44. In terms of profitability, NOVN's ROE is -1.71%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, NOVN is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check CPRX's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ALMS has a market cap of 3B. Regarding current trading prices, NOVN is priced at $0.09, while ALMS trades at $28.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ALMS's P/E ratio is -13.44. In terms of profitability, NOVN's ROE is -1.71%, compared to ALMS's ROE of -0.76%. Regarding short-term risk, NOVN is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ALMS's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, LQDA has a market cap of 3B. Regarding current trading prices, NOVN is priced at $0.09, while LQDA trades at $34.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas LQDA's P/E ratio is -23.55. In terms of profitability, NOVN's ROE is -1.71%, compared to LQDA's ROE of -2.97%. Regarding short-term risk, NOVN is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check LQDA's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, ARQT has a market cap of 3B. Regarding current trading prices, NOVN is priced at $0.09, while ARQT trades at $24.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas ARQT's P/E ratio is -70.94. In terms of profitability, NOVN's ROE is -1.71%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, NOVN is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check ARQT's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, VCYT has a market cap of 2.9B. Regarding current trading prices, NOVN is priced at $0.09, while VCYT trades at $36.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas VCYT's P/E ratio is 95.45. In terms of profitability, NOVN's ROE is -1.71%, compared to VCYT's ROE of +0.05%. Regarding short-term risk, NOVN is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check VCYT's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, NOVN is priced at $0.09, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas MORF's P/E ratio is -14.88. In terms of profitability, NOVN's ROE is -1.71%, compared to MORF's ROE of -0.29%. Regarding short-term risk, NOVN is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check MORF's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, NOVN is priced at $0.09, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas MOR's P/E ratio is -12.64. In terms of profitability, NOVN's ROE is -1.71%, compared to MOR's ROE of -1.84%. Regarding short-term risk, NOVN is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check MOR's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, VERA has a market cap of 2.8B. Regarding current trading prices, NOVN is priced at $0.09, while VERA trades at $39.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas VERA's P/E ratio is -9.94. In terms of profitability, NOVN's ROE is -1.71%, compared to VERA's ROE of -0.60%. Regarding short-term risk, NOVN is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check VERA's competition here

NOVN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NOVN stands at 2.6M. In comparison, BEAM has a market cap of 2.8B. Regarding current trading prices, NOVN is priced at $0.09, while BEAM trades at $27.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NOVN currently has a P/E ratio of -0.11, whereas BEAM's P/E ratio is -6.22. In terms of profitability, NOVN's ROE is -1.71%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, NOVN is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for NOVN.Check BEAM's competition here